Braveheart Bio (NASDAQ:BRVE) Earns “Overweight” Rating from Cantor Fitzgerald

Braveheart Bio (NASDAQ:BRVE)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a report issued on Tuesday, Benzinga reports. They currently have a $40.00 target price on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 110.15% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. TD Cowen initiated coverage on Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating for the company. The Goldman Sachs Group started coverage on Braveheart Bio in a report on Monday, August 31st. They issued a “buy” rating and a $48.00 target price on the stock. Jefferies Financial Group started coverage on Braveheart Bio in a research report on Monday, August 31st. They issued a “buy” rating and a $48.00 price target on the stock. Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a research note on Saturday, August 15th. Finally, Zacks Research upgraded shares of Braveheart Bio to a “hold” rating in a research note on Tuesday, September 1st. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Braveheart Bio has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

Braveheart Bio Stock Down 0.9%

Braveheart Bio stock opened at $19.03 on Tuesday. The company has a market cap of $1.71 billion and a P/E ratio of -7.58. The firm’s fifty day simple moving average is $24.50. Braveheart Bio has a 1-year low of $17.86 and a 1-year high of $32.00.

Braveheart Bio (NASDAQ:BRVE) last issued its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($2.26). As a group, equities research analysts anticipate that Braveheart Bio will post -1.48 EPS for the current year.

Insider Activity

In other news, Director Christopher Viehbacher bought 83,333 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $18.00 per share, with a total value of $1,499,994.00. Following the acquisition, the director owned 609,519 shares in the company, valued at $10,971,342. This trade represents a 15.84% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Erez Chimovits bought 1,940,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average price of $18.00 per share, with a total value of $34,920,000.00. Following the transaction, the director directly owned 11,901,826 shares in the company, valued at $214,232,868. This represents a 19.47% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 8,751,942 shares of company stock valued at $157,534,956.

About Braveheart Bio

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.